Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Researchers used a rationally designed, small synthetic analog of the CD4 protein surface to inhibit
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury